Skip to content
Film Television Auditions – Lifestyle
Author:
Alumis Inc.
Envudeucitinib Long-term Data Positioned to Set a New Standard for Plaque Psoriasis Treatment, Delivering Highest Reported PASI 100 Skin Clearance Among Oral Therapies
August 10, 2026
Alumis Reports First Quarter 2026 Financial Results and Highlights Recent Achievements
May 15, 2026
Alumis’ Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis
March 28, 2026
Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements
March 20, 2026
Alumis Announces Late-Breaker Oral Presentation of Phase 3 Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis at 2026 American Academy of Dermatology Annual Meeting
March 18, 2026